Investor Watch Series | Funding – Who to Watch | Novavax ProFactor Pharma | CureVac | S2 E3

Jul 18, 2020 | Digital Media, Investor Watch Series, Video

TrialSite News

Welcome To Investor Watch

In this series will be going over trials, research and other clinical verticals that receive funding. Below are the ones we cover in this episode:

  • U.S. Feds via Operation Warp Speed Injects $1.6b into Vaccine Maker Novavax: Introducing NVX-CoV2373: With growing tensions between Moderna and U.S. government scientists, Operation Warp Speed moved the investigational vaccine spotlight to NVX-CoV2373, the experimental vaccine from publicly traded Novavax Inc. (a late stage biotechnology company developing next-generation vaccines for serious infectious diseases). Not only did Novavax join the Operation Warp Speed Program, they became the largest funded vaccine developer to date with a $1.6 billion award by the federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial as well as establish large-scale manufacturing and deliver 100 million doses of NVX-CoV2373 as early as late 2020. A small and not well known Australian clinical research organization (CRO) called Nucleus Network will be under the spotlight as they lead the Novavax Phase 1/2 clinical trial in that country. https://www.trialsitenews.com/u-s-fed…
  • ProFactor Pharma Raises more Capital in Pursuit of Clinical Trials in Bid Drive Down Price of Recombinant Factor VIII: Thanks to meeting an important development milestone underlying a drive to absolutely transform the treatment of the blood clotting disorder Haemophilia A, Scotland-based ProFactor Pharma (PFP) recently received £1.1 million in the second tranche of support from a £2 million funding round announced in September 2019 to advance the development program. As it progresses towards toxicology, the Scottish venture has clinical trials in sight next year. The market needs a successful way to produce more recombinant Factor VIII at a lower cost to serve hundreds of thousands of underserved patients. https://www.trialsitenews.com/profact…
  • Vanderbilt U & Purdue Translational Breakthrough Identifies Monoclonal Antibody Capable of Preventing Acute Flaccid Myelitis: A team of researchers from Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated potential human monoclonal antibodies potentially capable of preventing acute flaccid myelitis (AFM), a rare but devastating polio-like illness in children linked to a respiratory viral infection called acute flaccid myelitis. https://www.trialsitenews.com/vanderb…
  • CureVac Secures €75 million Loan from European Investment Bank to Develop COVID-19 Vaccine CvnCoV: An innovative clinical-stage biotech company developing transformative medicines based on an optimized mRNA technology platform just secured €75 million in a loan agreement with the European Investment Bank (EIB). With a mRNA-based COVID-19 vaccine candidate, CureVac actually was invited to the U.S. White House to talk about an exclusive deal with the U.S. government, according to reports. The company wasn’t interested and, with new capital access, focuses on CVnCoV, the mRNA-based vaccine candidate targeting SARS-CoV-2 infection. https://www.trialsitenews.com/curevac…

0 Comments

Pin It on Pinterest